Search Results - "Hematological oncology"

Managing the toxicities of CAR T‐cell therapy by Neelapu, Sattva S.

“…Chimeric antigen receptor (CAR) T‐cell therapy has the potential to revolutionize the management of B‐cell lymphomas and possibly other cancers. Two anti‐CD19…”
Get full text

Multiple myeloma: Every year a new standard? by Rajkumar, S. Vincent

“…The treatment of myeloma is rapidly evolving. This article reviews the current diagnostic criteria, risk stratification, and approach to treatment of multiple…”
Get full text

CAR T‐cell therapy: Full speed ahead by Sermer, David, Brentjens, Renier

“…Chimeric antigen receptor (CAR) T‐cell therapy has dramatically shifted the landscape of treatment for lymphoid malignancies, especially diffuse large B‐cell…”
Get full text

Cutaneous T‐cell lymphomas—An update 2021 by Kempf, Werner, Mitteldorf, Christina

“…Cutaneous T‐cell lymphomas (CTCL) represent the majority of primary cutaneous lymphomas (CL). Mycosis fungoides (MF) and cutaneous CD30+ lymphoproliferative…”
Get full text

The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid by Hiemcke‐Jiwa, Laura S., Minnema, Monique C., Radersma‐van Loon, Joyce H., Jiwa, N. Mehdi, Boer, Mirthe, Leguit, Roos J., Weger, Roel A., Huibers, Manon M.H.

“…The gold standard for diagnosis of central nervous system lymphomas still regards a stereotactic brain biopsy, with the risk of major complications for the…”
Get full text

Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis by Schmitt, Andreas M., Herbrand, Amanda K., Fox, Christopher P., Bakunina, Katerina, Bromberg, Jacoline E.C., Cwynarski, Kate, Doorduijn, Jeanette K., Ferreri, Andrés J.M., Illerhaus, Gerald, Issa, Samar, Schorb, Elisabeth, Zucca, Emanuele, Hemkens, Lars G., Schandelmaier, Stefan, Kasenda, Benjamin

“…The CD‐20 antibody rituximab is a standard component of treatment of non‐Hodgkin B‐cell lymphomas, including diffuse large B‐cell lymphoma (DLBCL). Primary…”
Get full text

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart by Caocci, Giovanni, Mulas, Olga, Abruzzese, Elisabetta, Luciano, Luigiana, Iurlo, Alessandra, Attolico, Immacolata, Castagnetti, Fausto, Galimberti, Sara, Sgherza, Nicola, Bonifacio, Massimiliano, Annunziata, Mario, Gozzini, Antonella, Orlandi, Ester Maria, Stagno, Fabio, Binotto, Gianni, Pregno, Patrizia, Fozza, Claudio, Trawinska, Malgorzata Monika, De Gregorio, Fiorenza, Cattaneo, Daniele, Albano, Francesco, Gugliotta, Gabriele, Baratè, Claudia, Scaffidi, Luigi, Elena, Chiara, Pirillo, Francesca, Scalzulli, Emilia, La Nasa, Giorgio, Foà, Robin, Breccia, Massimo

“…Arterial occlusive events (AOEs) represent emerging complications in chronic myeloid leukemia (CML) patients treated with ponatinib. We identified 85…”
Get full text

Circ_0009910 shuttled by exosomes regulates proliferation, cell cycle and apoptosis of acute myeloid leukemia cells by regulating miR‐5195‐3p/GRB10 axis by Wang, Di, Ming, Xi, Xu, Jinhuan, Xiao, Yi

“…The exosomes are involved in intercellular communication via RNA trafficking in human diseases. Hsa_circ_0009910 (circ_0009910) is a novel leukemia‐related…”
Get full text

Cutaneous lymphomas—An update 2019 by Kempf, Werner, Zimmermann, Anne‐Katrin, Mitteldorf, Christina

“…Primary cutaneous lymphomas (CL) are the second most common form of extranodal lymphomas. Cutaneous T‐cell lymphomas represent the majority. They are…”
Get full text

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper by Cuneo, Antonio, Barosi, Giovanni, Danesi, Romano, Fagiuoli, Stefano, Ghia, Paolo, Marzano, Alfredo, Montillo, Marco, Poletti, Venerino, Viale, Pierluigi, Zinzani, Pier Luigi

“…The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib,…”
Get full text

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding by Boriani, Giuseppe, Corradini, Paolo, Cuneo, Antonio, Falanga, Anna, Foà, Robin, Gaidano, Gianluca, Ghia, Paolo Prospero, Martelli, Maurizio, Marasca, Roberto, Massaia, Massimo, Mauro, Francesca Romana, Minotti, Giorgio, Molica, Stefano, Montillo, Marco, Pinto, Antonio, Tedeschi, Alessandra, Vitolo, Umberto, Zinzani, Pier Luigi

“…The Bruton tyrosine kinase inhibitor ibrutinib (IB) has attained an important role in the treatment of patients with chronic lymphocytic leukaemia, mantle cell…”
Get full text

Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study by Durmo, Rexhep, Donati, Benedetta, Rebaud, Louis, Cottereau, Anne Segolene, Ruffini, Alessia, Nizzoli, Maria Elena, Ciavarella, Sabino, Vegliante, Maria Carmela, Nioche, Christophe, Meignan, Michel, Merli, Francesco, Versari, Annibale, Ciarrocchi, Alessia, Buvat, Irene, Luminari, Stefano

“…We evaluated the prognostic role of the largest distance between two lesions (Dmax), defined by positron emission tomography (PET) in a retrospective cohort of…”
Get full text

Primary central nervous system lymphoma: A curable disease by Batchelor, Tracy T.

“…Primary central nervous system lymphoma is a rare subtype of non‐Hodgkin lymphoma that is confined to the brain, leptomeninges, or the eye and is associated…”
Get full text

Bispecific antibodies for the treatment of lymphomas: Promises and challenges by Schuster, Stephen J.

“…The potential of bispecific antibodies to direct antigen‐specific T cell‐mediated cytotoxicity toward malignant cells bearing a target antigen was recognized…”
Get full text

Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials by Das, Avash, Dasgupta, Subhajit, Gong, Yan, Shah, Urvi A., Fradley, Michael G., Cheng, Richard K., Roy, Bhaskar, Guha, Avirup

“…We aim to determine the cumulative and comparative risk of cardiovascular events associated with different Immunomodulatory Drugs (iMiDs) and Proteasome…”
Get full text

Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome by Klein, Alina, Polliack, Aaron, Gafter‐Gvili, Anat

“…Patients with rheumatoid arthritis (RA) have a greater risk of developing both Hodgkin lymphoma (HL) and non‐HL than the general population. Non‐Hodgkin…”
Get full text

Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection by Pasquini, Zeno, Toschi, Alice, Casadei, Beatrice, Pellegrini, Cinzia, D’Abramo, Alessandra, Vita, Serena, Beccacece, Alessia, Bussini, Linda, Chionsini, Maria Clara, Dentale, Nicola, Cantiani, Alessia, Lazzarotto, Tiziana, Bartoletti, Michele, Nicastri, Emanuele, Zinzani, Pierluigi, Giannella, Maddalena, Viale, Pierluigi

“…Despite global vaccination efforts, immunocompromized patients remain at high risk for COVID‐19‐associated morbidity. In particular, patients with impaired…”
Get full text

Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches by Silkenstedt, Elisabeth, Dreyling, Martin

“…Mantle cell lymphoma (MCL) is clinically characterized by its heterogenous behavior with courses ranging from indolent cases that do not require therapy for…”
Get full text

Current understanding of tumor lysis syndrome by Rahmani, Benjamin, Patel, Shrey, Seyam, Omar, Gandhi, Jason, Reid, Inefta, Smith, Noel, Khan, Sardar Ali

“…Tumor lysis syndrome (TLS) is an oncologic emergency from the intracellular release of material in lysing malignant cells. The earlier it is treated, the less…”
Get full text

Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor by Bairey, Osnat, Shacham-Abulafia, Adi, Shpilberg, Ofer, Gurion, Ronit

“…This study compared the value of several simple laboratory parameters with known prognostic models for predicting survival in patients with diffuse large…”
Get full text